We use cookies to ensure that we give you the best experience on our website Learn more

Jan 12, 2018

International Diabetes Federation 2017 Congress

BALANCE study: safety and efficacy of Gemigliptin and Rosuvastatin as fixed dose combination therapy

;

Bae, J.C.;

Min, K.;

Kim, Y.H.;

Kim, K.A.;

Hong, E.G.;

Park, C.Y.;

Han, S.;

Yoon, H.;

Cha, B.S.

dpp4-inhibitor

gemigliptin

diabetes type 2

combination therapy

Abstract

Abstract

thumbnail

Keywords

dpp4-inhibitor

gemigliptin

diabetes type 2

combination therapy

Abstract

BALANCE study : Safety and Efficacy of Gemigliptin and Rosuvastatin as Fixed dose combination therapy Ji Cheol Bae, Kyungwan Min, Yong Hyun Kim, Kyoung-ah Kim, Eun-Gyoung Hong, Cheol-Young Park, Song Han, Hye Jin Yoon, Bong-Soo Cha Background Diabetes is highly likely to be accompanied with dyslipidemia and the risk of cardiovascular disease occurrence is significantly increased. Controlling of blood glucose and LDL-C in patients with type 2 diabetes mellitus (T2DM) have direct effects on the occurrence of cardiovascular disease, a complex treatment approach is necessary. Aim This study was to demonstrate the efficacy and safety of the fixed-dose combination (FDC) therapy of gemigliptin, a potent and selective DPP-4 inhibitor and rosuvastatin, a potent HMG-CoA reductase inhibitor compared to each mono-therapy in T2DM patients with dyslipidemia. Method In this randomized, placebo-controlled, double-blind, phase III trial, a total 290 T2DM patients with dyslipidemia who couldn’t achieve adequate glycemic control with more than 6 weeks before screening of stable metformin mono therapy (≥1000mg/day) were randomized (1:1:1) to gemigliptin/ rosuvastatin FDC (n=96), gemigliptin (n=97) or rosuvastatin (n=97). Subjects received gemigliptin 50 mg and rosuvastatin with forced up-titration from 5 mg to 20 mg at 8-week interval, while maintained metformin dose during the study period. The primary endpoints were changes from baseline in HbA1c and low-density lipoprotein cholesterol (LDL-C) after 24 weeks. Results : Baseline demographics and clinical characteristics were well balanced among treatment groups (mean HbA1c 7.79 ± 0.78 %; LDL-C 136.3 ± 27.8 mg/dL; age 55.9 ± 10.1 years; BMI 25.5 ± 3.2 kg/m2, duration of T2DM 6.6 ± 5.7 years). At 24 weeks, the LSM (least square mean+SE) difference of change of HbA1c (%) [(gemigliptin/rosuvastatin FDC)-(rosuvastatin)] was -0.81 ± 0.11% [95% CI(-1.04, -0.59)] and the LSM difference of % change of LDL-C (mg/dL) [(gemigliptin/rosuvastatin FDC)-(gemigliptin)] was -51.9 ± 2.7 % [95% CI (-57.3, -46.5)]. The differences in proportions achieving an HbA1c < 7% or LDL-C < 100 mg/dL were also statistically significant (p<0.001) between the FDC and the mono-therapy group, respectively. There were no significant differences in adverse event among gemigliptin/rosuvastatin FDC, gemigliptin and rosuvastatin group(45.8%, 30.9% and 39.2% respectively). Discussion Gemigliptin/rosuvastatin FDC helps to achieve adequate blood glucose and LDL-C levels, it is expected that gemigliptin/rosuvastatin FDC could be a new therapeutic choice in T2DM patients with dyslipidemia.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.